+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Role of indomethacin in ductus closure: an update evaluation

Role of indomethacin in ductus closure: an update evaluation

Developmental Pharmacology and Therapeutics 11(4): 196-212

Patent ductus arteriosus (PDA) in premature infants is a current challenge to pediatricians. Pharmacological closure of PDA with indomethacin, a prostaglandin synthetase inhibitor is an effective drug therapy, along with usual medical treatment. Administration of indomethacin may decrease mortality and morbidity (e.g. bronchopulmonary dysplasia) among very small premature infants (less than 1,000 g). Co-administration of furosemide with indomethacin may lessen the transient renal side effects of indomethacin. The therapeutic efficacy of indomethacin in closure of PDA depends largely on understanding and manipulation of the pharmacokinetic characteristics of the drug in preterm infants. Maintaining a therapeutic level of the drug in plasma is essential to achieve an optimal therapeutic response. Compared to surgical ligation, indomethacin is a noninvasive, less expensive and safer therapy for ductus closure.

(PDF emailed within 1 workday: $29.90)

Accession: 006351024

Download citation: RISBibTeXText

PMID: 3066603

Related references

Evaluation of indomethacin in closure of the ductus arteriosus. Circulation Supplement 56(4): III-192, 1977

Factors associated with permanent closure of the ductus arteriosus: a role for prolonged indomethacin therapy. Pediatrics 110(1 Pt 1): E10-E10, 2002

Evaluation of persistent ductus arteriosus closure by indomethacin and ligation with pulsed doppler velocimetry. Clinical Research 34(4): 976A, 1986

Indomethacin and the preterm infant with a patent ductus arteriosus: relationship between plasma concentration and ductus closure. Developmental Pharmacology and Therapeutics 4(1-2): 37-46, 1982

Reopening of the ductus arteriosus after closure with indomethacin: importance of sustained effective indomethacin serum concentrations. Journal of Pediatrics 128(5 Pt 1): 719-719, 1996

Relationship of serum indomethacin levels to ductus arteriosus closure in extremely premature infants treated with prophylactic indomethacin. Pediatric Research 39(4 PART 2): 203A, 1996

Escalating dose indomethacin for prophylactic closure of patent ductus arteriosus does not improve closure rates and is associated with increased complications. Journal of Pediatrics 154(1): 153-153, 2009

Persistent responsiveness of the neonatal ductus arteriosus in immature lambs: a possible cause for reopening of patent ductus arteriosus after indomethacin-induced closure. Circulation 71(1): 141-145, 1985

Problems with indomethacin for ductus closure. Lancet 2(8031): 245-245, 1977

Indomethacin in closure of patent ductus arteriosus. Indian Journal of Pediatrics 48(393): 477-480, 1981

Indomethacin and furosemide in closure of ductus arteriosus. Boletin Medico del Hospital Infantil de Mexico 43(8): 482-488, 1986

Re opening of the ductus arteriosus after indomethacin closure. Pediatric Research 18(4 PART 2): 315A, 1984

Early closure of ductus arteriosus with indomethacin. Klinische Padiatrie 197(2): 172-172, 1985

Indomethacin for closure of patent ductus arteriosus in prematures. Clinical Pediatrics 21(4): 217-220, 1982

Indomethacin: pharmacologic closure of the ductus arteriosus. MCN pharmacopoeia. Mcn. American Journal of Maternal Child Nursing 7(3): 171-171, 1982